Health

By age 25, Patrick Schnur had cycled through a series of treatment programs, trying different medications to kick his heroin habit. But the drugs posed problems too: Vivitrol injections were painful and created intense heroin cravings as the drug wore off. Suboxone left him drowsy, depressed and unable to study or go running like he wanted to. Determined to resume the life he had before his addiction, Schnur decided to hunker down and get clean on his own.

In December 2015, he had been sober for two years and had just finished his first semester of college, with a 4.0 grade point average. Yet, just before the holidays, he gave in to the cravings. Settling into his dorm room he stuck a needle in his vein. It was his last shot.
Scientists are searching for a different kind of shot to prevent such tragedies: a vaccine to counter addiction to heroin and other opioids, such as the prescription painkiller fentanyl and similar knockoff drugs. In some ways, the vaccines work like traditional vaccines for infectious diseases such as measles, priming the immune system to attack foreign molecules. But instead of targeting viruses, the vaccines zero in on addictive chemicals, training the immune system to usher the drugs out of the body before they can reach the brain.

Such a vaccine may have helped Schnur, a onetime computer whiz who grew up in the Midwest, far removed from the hard edges of the drug world. His overdose death reflects a growing heroin epidemic and alarming trend. In the 1960s, heroin was seen as a hard-core street drug abused mostly in inner cities. Now heroin is a problem in many suburban and rural towns across America, where it is used primarily by young, white adults — male and female, according to research published by psychiatrist Theodore Cicero of Washington University in St. Louis and colleagues in 2014 in JAMA Psychiatry.
His team’s surveys of nearly 2,800 patients in substance abuse treatment programs suggest a shift in the demographics of heroin users in recent years. In the 1960s, more than 80 percent of users took heroin as their first opioid. From 2000 to 2010, 75 percent of heroin users came to the drug because it was easier to get and less expensive than the prescription opioids they had been taking.

In recent decades, overdoses of both illicit and prescription drugs have surged. In 2014, overdose deaths surpassed deaths from motor vehicle accidents, the U.S. Centers for Disease Control and Prevention reported in January. In that year, 28,647 people died of opioid-related overdoses, primarily from prescription pain relievers and heroin.

“The opioid epidemic is devastating and the number of people dying demands an urgent intervention,” says Nora Volkow, director of the U.S. National Institute on Drug Abuse.

A family of drugs
The term opioid refers to a host of painkillers derived from the opium poppy as well as synthetic versions of its active compounds. Heroin is processed from morphine, which is extracted from the plant. Prescription medications such as Vicodin, Percocet, OxyContin and fentanyl are made from synthetic morphine, altered to produce different effects.

Currently, three medications, sold under various brand names, are available to help people with heroin or opioid addiction get clean and stay drug-free: methadone, buprenorphine and naltrexone. The treatments work, Volkow says, but not perfectly. Some addicted patients, such as Schnur, experience unwanted side effects from the daily or monthly treatments and stop using them. Others lack access to treatments due to high costs and strict federal limits on dispensing the drugs.

“Unfortunately, only a small percentage — about 25 percent — of people who could benefit from treatment actually get these medications,” Volkow says.
Round two for vaccines
Vaccines could offer an alternative to patients who have kicked their habit and want to stay clean, scientists say. The vaccines aim to make an addict immune to a drug’s effects, decreasing the motivation to seek more of the drug. That’s important, Volkow says, because over time the treatment may allow recovery of the overactive circuitry in the brain that pushes drug users to keep using.

The idea of antidrug vaccines isn’t new. Scientists began working on formulations in the 1970s, but those efforts were eclipsed by the availability of methadone. Methadone, a synthetic opioid, relieves withdrawal symptoms and cravings for heroin or prescription painkillers by acting on the same brain targets as the drugs, but in a slow, controlled manner, so patients can function normally without feeling high. But the treatment is a method for harm reduction, not a cure for addiction, and must be taken daily to be effective.

In the late 1990s, scientists resumed antidrug vaccine efforts, focusing on vaccines for everything from cocaine to nicotine to heroin (SN: 2/10/07, p. 90). Vaccines for nicotine and cocaine were tested in people, but worked for only a small percentage.

Now, to help combat the growing opioid addiction crisis, two vaccines for heroin users are advancing toward human trials and other antiopioid vaccines are in the pipeline, including one for fentanyl, now a popular street drug.

Among the antiheroin vaccines being tested, one — developed at the Scripps Research Institute in La Jolla, Calif. — spurs the immune system to attack heroin and helps eliminate it from the body so effectively that it can neutralize even lethal levels of the drug in animals. A second anti­heroin vaccine, developed at the Walter Reed Army Institute of Research in Silver Spring, Md., goes after two closely linked problems: It keeps heroin from reaching the brain while preventing HIV infection.

Addiction’s grip
Once a person is addicted, the fight to stay clean never ends, Volkow says. That’s because heroin and other addictive substances alter the brain’s pleasure circuits, producing changes that persist long after users stop taking the drug. Volkow, who has studied these effects for more than two decades, says addiction is a brain disease because of the structural and functional changes that occur.
Drugs of abuse produce their high by interacting with cells located in brain areas that govern reward, including the nucleus accumbens, a key region in the pleasure circuit. Though each type of drug works in a slightly different way, all addictive drugs increase the amount of the chemical dopamine in this area. Dopamine is a neurotransmitter, carrying signals between nerve cells, or neurons.

Opioids boost dopamine levels by stimulating molecules called mu receptors that sit on the surface of certain neurons. Normally, these receptors are activated by hormones and brain chemicals made in the body, such as endorphins, to reinforce pleasurable behavior such as eating, having sex or listening to music. A single dose of heroin, however, releases many times the amount of dopamine produced by a favorite food or song.

Dopamine fuels the high that people feel from taking an addictive drug, but other molecules help to get people hooked. Glutamate, a neurotransmitter that increases the chatter among cells in areas that govern learning and boost motivation, helps engrave the experience of a drug’s high into the brain. Memories of the high become so enduring that years later they can be reawakened. This long-lasting pull is why more than 60 percent of people with addiction experience relapse within the first year after they are discharged from treatment.

Taken over time, drugs of abuse can change signaling in a number of the brain’s circuits. Last year in Cell, Volkow and NIDA biochemist Marisela Morales outlined two common features of the addicted brain: a decreased sensitivity in the brain’s reward centers and disruption of circuits involved in self-control.

With repeated drug use, the number of dopamine receptors declines as the brain attempts to calm down, Volkow says. With fewer receptors available to take up dopamine molecules, it takes more stimulation to produce feelings of pleasure. Addicts soon find that they are no longer motivated by everyday activities that had been enjoyable or exciting, and they need higher doses of the drug to get the euphoric feelings once provided by smaller doses.

“The brain rapidly learns that the only thing that’s going to stimulate these pleasure circuits is the drug,” Volkow says. “That’s one of the components that drives drug-seeking behavior.” Eventually, the drug no longer produces a high. Instead, it becomes a necessity to stave off feelings of anxiety and despair.

Addiction also impairs dopamine functioning in the prefrontal cortex, an area of the brain that includes regions involved in analysis, decision making and self-control. “Taking drugs interferes with one’s capacity to make good decisions” and follow through, Volkow says. “An addict might say ‘I don’t want to take that drug.’ But they don’t have the capacity to easily change their behavior.”

Protect the brain
Vaccines, potentially, offer a “transformative” way to treat addiction, Volkow says, because the treatments can train the immune system to attack drug molecules before they reach the brain. Vaccines typically contain an agent that resembles a disease-causing virus, teaching the immune system to respond quickly when it encounters the invader. In designing vaccines, scientists try to provoke at least one of the human body’s primary immune responders: T cells, which attack infected cells, or B cells, which release antibodies that recognize hostile molecules and attach to them, targeting them for destruction.

Easier said than done. For starters, drug molecules are tiny, much smaller than a bacterium or virus, and are not easily detected by the immune system. In addition, the body’s immune system is set up to fight invaders that arrive in small groups. When an influenza virus makes its way into a body, the initial levels of virus in the blood are very low, Volkow says. But when people inject heroin, for example, many millions of drug molecules and their breakdown products quickly rush into the bloodstream. In recent years, researchers have found new ways to help call the immune system’s attention to such surges of “invading” drugs.

While developing one heroin vaccine, chemist Kim Janda of Scripps and colleagues noticed that antibodies to heroin molecules alone didn’t stop animals from getting high. That’s because once heroin gets into the body — whether it’s injected, snorted or smoked — it is broken down into its active components, 6-acetylmorphine, or 6-AM, and morphine. “Those two metabolites are the real drugs in heroin,” Janda says.

Typically, vaccines lead to production of antibodies that target a single invader. To get the immune system to notice both heroin and its metabolites, Janda joined forces with neurobiologist George Koob, director of the National Institute on Alcohol Abuse and Alcoholism, to design a multitarget vaccine. The vaccine “cocktail,” as Janda calls it, has three components: a large protein that carries the druglike molecules into the body; a molecule called a hapten, chemically designed to induce an immune response to heroin and its metabolites 6-AM and morphine; and finally, alum, an agent commonly added to vaccines to stimulate release of cytokines, proteins that help rally the immune cells to fight invaders.

Over the last six years, Janda’s group has tinkered with the hapten to help the antibodies get a tight grip on heroin, 6-AM and morphine. The hapten, along with the protein carrier, draws attention from the immune system’s T cells, which learn to recognize the drug molecules as invaders. Later, if heroin or its metabolites are detected in the blood, the T cells will “remember” the invaders and remove them.
In rats, the three-pronged vaccine generated high numbers of antibodies against the drug and its metabolites, blocking heroin’s action on the brain. Once vaccinated, the formerly addicted rats were unable to get high, even when injected with extremely high doses of the drug, Janda’s group reported in 2013 in the Proceedings of the National Academy of Sciences. The result was decreased drug-seeking behavior in the vaccinated rats. By contrast, control rats, and those vaccinated only against morphine, continued to seek higher doses of the drug.

The vaccine showed similar effectiveness in nonhuman primates, Janda reported in May at the American Psychiatric Association’s annual meeting in Atlanta. In addition, the vaccine is specific to heroin metabolites, not other opiates. A vaccine that’s too broad could potentially make patients immune to the effects of all prescription opioids, leaving them vulnerable if they become injured and need pain relief.

Janda’s team recently tested another antiopioid vaccine in animals, one that arms the body against fentanyl. When given to mice, the vaccine trained the animals’ immune systems to generate antibodies that bind to fentanyl and prevent it from traveling to the brain from the bloodstream. The results, published March 7 in Angewandte Chemie, showed that in mice, the antibodies neutralized high levels of the drug — more than 30 times a normal dose — for months after a series of three shots. By blocking the effects of the drug and its high, the vaccine could potentially curb drug-seeking behavior.

Another group is going after heroin and its strong tie to high HIV infection rates worldwide. Scientists at the Walter Reed Army Institute of Research are developing a dual-purpose vaccine, called H2, to treat heroin addiction while preventing HIV infection.

Biochemist Gary Matyas and his group at Walter Reed first designed a vaccine to stimulate antibodies against heroin. Similar to Janda’s antiheroin vaccine, haptens are bound to a protein carrier, spurring the immune system to create high levels of antibody to bind heroin and its metabolites in the blood and prevent it from crossing the blood-brain barrier. Users will then experience no euphoria or addictive reactions.

The researchers plan to combine the heroin vaccine with an HIV vaccine, a combination that’s much trickier to develop. Scientists have long been frustrated by the ability of the AIDS virus to mutate and evade the immune system. The virus constantly changes the makeup of the proteins on its surface so that antibodies have difficulty recognizing and attacking it. But researchers have found that targeting a region called V2 on the surface of the virus decreased the risk of HIV infection.

The vaccine, tested in volunteers in Thailand by the country’s Ministry of Public Health and Walter Reed scientists, protected about a third of participants against HIV infection, according to a 2009 report.

There’s no timeline for moving the H2 vaccine into human trials, Matyas says. His hope is that the vaccine will concurrently address the entwined epidemics. “If you can reduce heroin use, you can reduce the spread of HIV,” he says. “That’s why we’re focusing on both heroin and HIV in one vaccine.”

Extra help
While vaccines can’t be the only treatment for the opioid epidemic, they could offer users who want to abstain an additional and much needed option to deal with addiction. It’s not unusual for people to relapse, or to require more than one type of treatment, before finding a course of recovery that suits them, Volkow says.
Treating addiction like a disease that needs to be managed, such as diabetes or high blood pressure, with a multiplicity of treatment options would help addicts find a treatment that works well for them over the long haul, she says.

“Addiction is an extremely serious disease, with a high mortality rate and devastating consequences,” Volkow says. “We need to treat it very aggressively, and we need to have a variety of interventions so if one doesn’t work we have something else to offer the patient.”

Because relapse is common in addiction, Janda says he thinks that the antidrug vaccines’ value will come in helping people who want to abstain, but might falter in a weak moment. “Even if they try to do the drug, they’re not going to get the reward effects of the drug,” he says. “That means that they won’t spiral out of control and have to start all over again.”

Kathy Schnur, Patrick’s mother, remembers how, years into her son’s treatment, when the conversation turned to heroin — its euphoric high and mysterious spell — her son would confess to a desire to taste the drug “one more time.” A heroin vaccine would have taken a relapse off the table, she says. He would no longer have needed to make a daily decision to stay clean.

“If he knew he couldn’t get what he expected from the drug, it would remain a nonevent,” Schnur says. “Or, if he slipped up and tried it just one more time, the vaccine would prevent an overdose.”

Mars’ misshapen moons, Phobos and Deimos, might be all that’s left of a larger family that arose in the wake of a giant impact with the Red Planet billions of years ago, researchers report online July 4 in Nature Geoscience.

The origin of the two moons has never been clear; they could be captured asteroids or homegrown satellites. But their orbits are hard to explain if they were snagged during a flyby, and previous calculations have had trouble reproducing locally sourced satellites. The new study finds that a ring of rocks blown off of the planet by a collision with an asteroid could have been a breeding ground for a set of larger satellites relatively close to the planet. Those moons, long since reclaimed by Mars, could have herded remaining debris in the sparsely populated outer part of the ring to form Phobos and Deimos.
Pascal Rosenblatt, a planetary scientist at the Royal Observatory of Belgium in Brussels, and colleagues ran computer simulations to show how the helper moons formed, did their duty and then fell to Mars, leaving behind a pair of moons similar to Phobos and Deimos.

The rain of moons is not over. While Deimos is in a stable orbit, Phobos is developing stress fractures as it slowly inches toward the Red Planet (SN: 12/12/15, p. 11).

Using tools is very old monkey business.

Capuchins in northeast Brazil have wielded stones to crack open cashew nuts for 600 to 700 years, researchers report July 11 in Current Biology. Unearthed “hammers” and “anvils” are the earliest evidence of monkey tool use to date.

Today, Brazilian bearded capuchin monkeys (Sapajus libidinosus) still open cashews by placing them on the flat surfaces of anvil rocks and pounding the nuts with large stones. Unlike pebbles and other rocks, the tool stones are distinctively heavy, blemished with wear marks, greased with cashew residue and clustered under cashew trees, Michael Haslam of the University of Oxford and colleagues found.
The team mapped where the monkeys left these modern tools scattered under cashew trees. When the researchers dug beneath dense, ancient cashew groves, they found 69 more stone tools — clustered in similar arrangements to modern tools, of similar heft and with the same distinctive wear marks — buried in three sequentially deeper layers of sediment. Radiocarbon dating of charcoal shows that the deepest tools rest in a layer of excavated soil dating back as early as 1266, suggesting that capuchins have been using stone tools to crack nuts for hundreds of years.
The new findings are “incredibly important,” says archaeologist Huw Barton of the University of Leicester in England. They “will help us reassess the earliest evidence of tool use by our own ancestors.”

Capuchins are the only monkeys in South America that frequently use tools. It’s a habit they evolved independently from other inventive primates, such as humans and chimps. (The three species last shared a common ancestor some 35 million years ago.) Understanding why capuchins picked up the skill could point to situations that inspired the rise of tool use across species, says primatologist and study coauthor Tiago Falótico of the University of Sao Paulo.

Elisabetta Visalberghi, a primatologist at the Institute of Cognitive Sciences and Technologies in Rome, agrees that it’s likely that the monkeys “used tools in the past as they do now.” But she doubts that wear-and-tear scratches — which Haslam’s team used to identify buried stones as tools — were indeed produced by cracking cashews. The nuts are relatively soft; so are the stones, she says. While Haslam’s team compared markings on modern and ancient tools, they didn’t test if new marks appear on modern stones after they are used by capuchins. Visalberghi says those experiments are “fundamental to evaluate the relevance of the results.”
SUBSCRIBE
While this is not the first archaeological evidence of monkey tool use, it is the oldest by far. Haslam, Falótico and colleagues reported the first evidence last month in the Journal of Human Evolution: 10- to 50-year-old buried tools used by long-tailed macaques in Thailand. Before that, chimpanzees were the only primates other than humans with an ancient track record of tool use, dating back thousands of years (SN: 02/17/07, p. 99).

Compared with that of chimps, the record of capuchin tools is relatively young. But 600 to 700 years isn’t a final estimate, the researchers say. Even older monkey tools could rest in deeper soil under the cashew trees.

Turtle shells didn’t get their start as natural armor, it seems. The reptiles’ ancestors might have evolved partial shells to help them burrow instead, new research suggests. Only later did the hard body covering become useful for protection.

The findings might also help explain how turtles’ ancestors survived a mass extinction 250 million years ago that wiped out most plants and animals on earth, scientists report online July 14 in Current Biology.

Most shelled animals, like armadillos, get their shells by adding bony scales all over their bodies. Turtles, though, form shells by gradually broadening their ribs until the bones fuse together. Fossils from ancient reptiles with partial shells made from thickened ribs suggest that turtles’ ancestors began to suit up in the same way.
It’s an unusual mechanism, says Tyler Lyson, a paleontologist at the Denver Museum of Nature and Science who led the study. Thicker ribs don’t offer much in the way of protection until they’re fully fused, as they are in modern turtles. And the modification makes critical functions like moving and breathing much harder — a steep price for an animal to pay. So Lyson suspected there was some advantage other than protection to the partial shells.

He and his colleagues examined fossils from prototurtles, focusing on an ancient South African reptile called Eunotosaurus africanus.

Eunotosaurus shared many characteristics with animals that dig and burrow, the researchers found. The reptile had huge claws and large triceps in addition to thickened ribs.
“We could tell that this animal was very powerful,” says Lyson.
Broad ribs “provide a really, really strong and stable base from which to operate this powerful digging mechanism,” he adds. Like a backhoe, Eunotosaurus could brace itself to burrow into the dirt.

Thanks to a lucky recent find of a fossil preserving the bones around the eyes, the team was even able to tell that the prototurtles’ eyes were well adapted to low light. That’s another characteristic of animals that spend time underground.

Swimming and digging use similar motions, Lyson says, so you would expect to find similar skeletal adaptations in water-dwelling animals. But large claws good for moving dirt suggest a life on land.

Fossils from other prototurtle species also have wider ribs and big claws. So the researchers think these traits may have been important for early turtle evolution in general, not just for Eunotosaurus.

Not everyone is entirely convinced. “It’s a very plausible idea, although many other animals burrow but don’t have these specializations,” says Hans Sues, a paleontologist at the Smithsonian Institution’s National Museum of Natural History. Sues says that it will be important to find and study other turtle ancestors well-adapted to digging to bolster the explanation.

Lyson thinks the prototurtles’ burrowing tendencies might have helped them survive the end-Permian mass extinction around 250 million years ago (SN: 9/19/15, p. 10).

“Lots of animals at this time period burrowed underground to avoid the very, very arid environment that was present in South Africa,” Lyson says. “The burrow provides more climate control.”

There are plenty of reasons to tell kids not to bite their nails or suck their thumbs. Raw fingernail areas pick up infection, and thumbs can eventually move teeth into the wrong place. Not to mention these habits slop spit everywhere. But these bad habits might actually good for something: Kids who sucked their thumbs or chewed their nails had lower rates of allergic reactions in lab tests, a new study finds.

The results come from a group of more than 1,000 children in New Zealand. When the kids were ages 5, 7, 9 and 11, their parents were asked if the kids sucked their thumbs or bit their nails. At age 13, the kids came into a clinic for an allergen skin prick test. That’s a procedure in which small drops of common allergens such as pet dander, wool, dust mites and fungus are put into a scratch on the skin to see if they elicit a reaction.

Kids whose parents said “certainly” to the question of thumb-sucking or nail-biting were less likely to react to allergens in the skin prick test, respiratory doctor Robert Hancox of the University of Otago in New Zealand and colleagues report July 11 in Pediatrics. And this benefit seemed to last. The childhood thumb-suckers and nail-biters still had fewer allergic reactions at age 32.

The results fit with other examples of the benefits of germs. Babies whose parents cleaned dirty pacifiersby popping them into their own mouths were more protected against allergies. And urban babies exposed to roaches, mice and cats had fewer allergies, too. These scenarios all get more germs in and on kids’ bodies. And that may be a good thing. An idea called the hygiene hypothesis holds that exposure to germs early in life can train the immune system to behave itself, preventing overreactions that may lead to allergies and asthma.

It might be the case that germy mouths bring benefits, but only when kids are young. Hancox and his colleagues don’t know when the kids in their study first started sucking thumbs or biting nails, but having spent time around little babies, I’m guessing it was pretty early.

So does this result mean that parents shouldn’t discourage — or even encourage — these habits? Hancox demurs. “We don’t have enough evidence to suggest that parents change what they do,” he says. Still, the results may offer some psychological soothing, he says. “Perhaps if children have habits that are difficult to break, there is some consolation for parents that there might be a reduced risk of developing allergy.”

A puzzling mismatch is plaguing two methods for measuring how fast the universe is expanding. When the discrepancy arose a few years ago, scientists suspected it would fade away, a symptom of measurement errors. But the latest, more precise measurements of the expansion rate — a number known as the Hubble constant — have only deepened the mystery.

“There’s nothing obvious in the measurements or analyses that have been done that can easily explain this away, which is why I think we are paying attention,” says theoretical physicist Marc Kamionkowski of Johns Hopkins University.
If the mismatch persists, it could reveal the existence of stealthy new subatomic particles or illuminate details of the mysterious dark energy that pushes the universe to expand faster and faster.

Measurements based on observations of supernovas, massive stellar explosions, indicate that distantly separated galaxies are spreading apart at 73 kilometers per second for each megaparsec (about 3.3 million light-years) of distance between them. Scientists used data from NASA’s Hubble Space Telescope to make their estimate, presented in a paper to be published in the Astrophysical Journal and available online at arXiv.org. The analysis pegs the Hubble constant to within experimental errors of just 2.4 percent — more precise than previous estimates using the supernova method.

But another set of measurements, made by the European Space Agency’s Planck satellite, puts the figure about 9 percent lower than the supernova measurements, at 67 km/s per megaparsec with an experimental error of less than 1 percent. That puts the two measurements in conflict. Planck’s result, reported in a paper published online May 10 at arXiv.org, is based on measurements of the cosmic microwave background radiation, ancient light that originated just 380,000 years after the Big Bang.

And now, another team has weighed in with a measurement of the Hubble constant. The Baryon Oscillation Spectroscopic Survey also reported that the universe is expanding at 67 km/s per mega-parsec, with an error of 1.5 percent, in a paper posted online at arXiv.org on July 11. This puts BOSS in conflict with the supernova measurements as well. To make the measurement, BOSS scientists studied patterns in the clustering of 1.2 million galaxies. That clustering is the result of pressure waves in the early universe; analyzing the spacing of those imprints on the sky provides a measure of the universe’s expansion.

Although the conflict isn’t new (SN: 4/5/14, p. 18), the evidence that something is amiss has strengthened as scientists continue to refine their measurements.
The latest results are now precise enough that the discrepancy is unlikely to be a fluke. “It’s gone from looking like maybe just bad luck, to — no, this can’t be bad luck,” says the leader of the supernova measurement team, Adam Riess of Johns Hopkins. But the cause is still unknown, Riess says. “It’s kind of a mystery at this point.”
Since its birth from a cosmic speck in the Big Bang, the universe has been continually expanding. And that expansion is now accelerating, as galaxy clusters zip away from one another at an ever-increasing rate. The discovery of this acceleration in the 1990s led scientists to conclude that dark energy pervades the universe, pushing it to expand faster and faster.

As the universe expands, supernovas’ light is stretched, shifting its frequency. For objects of known distance, that frequency shift can be used to infer the Hubble constant. But measuring distances in the universe is complicated, requiring the construction of a “distance ladder,” which combines several methods that build on one another.

To create their distance ladder, Riess and colleagues combined geometrical distance measurements with “standard candles” — objects of known brightness. Since a candle that’s farther away is dimmer, if you know its absolute brightness, you can calculate its distance. For standard candles, the team used Cepheid variable stars, which pulsate at a rate that is correlated with their brightness, and type 1a supernovas, whose brightness properties are well-understood.

Scientists on the Planck team, on the other hand, analyzed the cosmic microwave background, using variations in its temperature and polarization to calculate how fast the universe was expanding shortly after the Big Bang. The scientists used that information to predict its current rate of expansion.

As for what might be causing the persistent discrepancy between the two methods, there are no easy answers, Kamionkowski says. “In terms of exotic physics explanations, we’ve been scratching our heads.”

A new type of particle could explain the mismatch. One possibility is an undiscovered variety of neutrino, which would affect the expansion rate in the early universe, says theoretical astrophysicist David Spergel of Princeton University. “But it’s hard to fit that to the other data we have.” Instead, Spergel favors another explanation: some currently unknown feature of dark energy. “We know so little about dark energy, that would be my guess on where the solution most likely is,” he says.

If dark energy is changing with time, pushing the universe to expand faster than predicted, that could explain the discrepancy. “We could be on our way to discovering something nontrivial about the dark energy — that it is an evolving energy field as opposed to just constant,” says cosmologist Kevork Abazajian of the University of California, Irvine.

A more likely explanation, some experts say, is that a subtle aspect of one of the measurements is not fully understood. “At this point, I wouldn’t say that you would point at either one and say that there are really obvious things wrong,” says astronomer Wendy Freedman of the University of Chicago. But, she says, if the Cepheid calibration doesn’t work as well as expected, that could slightly shift the measurement of the Hubble constant.

“In order to ascertain if there’s a problem, you need to do a completely independent test,” says Freedman. Her team is working on a measurement of the Hubble constant without Cepheids, instead using two other types of stars: RR Lyrae variable stars and red giant branch stars.

Another possibility, says Spergel, is that “there’s something missing in the Planck results.” Planck scientists measure the size of temperature fluctuations between points on the sky. Points separated by larger distances on the sky give a value of the Hubble constant in better agreement with the supernova results. And measurements from a previous cosmic microwave background experiment, WMAP, are also closer to the supernova measurements.

But, says George Efstathiou, an astrophysicist at the University of Cambridge and a Planck collaboration member, “I would say that the Planck results are rock solid.” If simple explanations in both analyses are excluded, astronomers may be forced to conclude that something important is missing in scientists’ understanding of the universe.

Compared with past disagreements over values of the Hubble constant, the new discrepancy is relatively minor. “Historically, people argued vehemently about whether the Hubble constant was 50 or 100, with the two camps not conceding an inch,” says theoretical physicist Katherine Freese of the University of Michigan in Ann Arbor. The current difference between the two measurements is “tiny by the standards of the old days.”

Cosmological measurements have only recently become precise enough for a few-percent discrepancy to be an issue. “That it’s so difficult to explain is actually an indication of how far we’ve come in cosmology,” Kamionkowski says. “Twenty-five years ago you would wave your hands and make something up.”

Talking about her cover story on what iron-loving elements are telling geologists about the Earth’s deep past, Alexandra Witze likens these rare metals to time travelers. They can tell you, she says, what was happening more than 4.5 billion years ago, during the first 50 million years of our planet’s existence. By then the Earth’s molten interior had begun to settle into its current layer cake form: a dense, solid inner core surrounded by an outer liquid core — both rich in iron and metals such as gold, platinum, ruthenium and others that tend to form alloys with iron. The scarcity of these metals in the outer layers of the planet — the mantle and crust — make them precious to us.
Their high melting points and other properties help them resist change, allowing geoscientists to use them as fingerprints that mark events in the distant past. With new, more precise analytic techniques, scientists can now measure the amounts of these iron-loving metals relative to other elements to deduce what happened to them over eons of time. These traces are found in some very old rocks, Witze reports (SN: 8/6/16, p. 22), such as 3.8-billion-year-old deposits in Greenland. But the metals also show up as ancient time capsules in younger rock. Studying these traces reveals the imperfect mixing of the mantle and can provide insight into outstanding questions, such as why amounts of these metals differ in the mantles of the moon and Earth.
Science is surprisingly adept at this type of virtual time travel. Researchers have repeatedly come up with ways to discover facts about the distant past. In this issue of Science News alone, several new findings illustrate the ability of science to figure out things that would seem impossibly difficult to know. A black hole in a distant galaxy formed over 13 billion years ago, for example, so long ago that it’s hard to even imagine reconstructing the events that led to its birth. But scientists have now pieced together clues, Christopher Crockett reports (SN: 8/6/16, p. 7), that it formed by the direct collapse of a massive gas cloud, rather than from the death of a massive star (the more common origin of black holes).

Reconstructing the evolution of the tail has been stymied by a lack of fossils from creatures that led the transition from water to land. But that hasn’t stopped scientists eager to explore the biomechanics of fishlike animals attempting to hop out of the water and up a slope. Studies of big-tailed fish called mudskippers highlight the utility of a tail in balancing flipper-hops up a sandy incline, Susan Milius reports (SN: 8/6/16, p. 13). To describe the math, scientists built a robot and made it scale an unsteady hill of shifty poppy seeds or plastic bits. Their conclusion: The tail could have been a big assist to flippered creatures emerging on sandy shores several hundred million years ago.

The story on Homo naledi by Bruce Bower (SN: 8/6/16, p. 12) shows why sometimes scientists might just prefer to actually time travel. Efforts to date the bones of this hominid species have proved frustrating; the latest estimate, 912,000 years old, was deduced from evolutionary trees. Knowing how old H. naledi actually is might reveal the diversity of relatively recent hominid species, and perhaps help piece together the story of how Homo sapiens became the sole survivors. That’s some time travel I’d be interested in booking.

Cancer goes way, way back. A deadly form of this disease and a noncancerous but still serious tumor afflicted members of the human evolutionary family nearly 2 million years ago, two new investigations of fossils suggest.

If those conclusions hold up, cancers are not just products of modern societies, as some researchers have proposed. “Our studies show that cancers and tumors occurred in our ancient relatives millions of years before modern industrial societies existed,” says medical anthropologist Edward Odes of the University of the Witwatersrand in Johannesburg, a coauthor of both new studies. Today, however, pesticides, longer life spans and other features of the industrialized world may increase rates of cancers and tumors.
A 1.6-million- to 1.8-million-year-old hominid, either from the Homo genus or a dead-end line called Paranthropus, suffered from a potentially fatal bone cancer, Odes and colleagues say in one of two papers published in the July/August South African Journal of Science. Advanced X-ray techniques enabled identification of a fast-growing bone cancer on a hominid toe fossil previously unearthed at South Africa’s Swartkrans Cave site, the researchers report. This malignant cancer consisted of a mass of bone growth on both the toe’s surface and inside the bone.

Until now, the oldest proposed cancer in hominids consisted of an unusual growth on an African Homo erectus jaw fragment dating to roughly 1.5 million years ago. Critics, though, regard that growth as the result of a fractured jaw, not cancer.

A second new study, led by biological anthropologist Patrick Randolph-Quinney, now at the University of Central Lancashire in England, identifies the oldest known benign tumor in a hominid in a bone from an
Australopithecus sediba child. This tumor penetrated deep into a spinal bone, close to an opening for the spinal cord. Nearly 2-million-year-old partial skeletons of the child and an adult of the same species were found in an underground cave at South Africa’s Malapa site ( SN: 8/10/13, p. 26 ).
Although not life-threatening, this tumor would have interfered with walking, running and climbing, the researchers say. People today, especially children, rarely develop such tumors in spinal bones.

“This is the first evidence of such a disease in a young individual in the fossil record,” Randolph-Quinney says.

X-ray technology allowed scientists to create and analyze 3-D copies of the inside and outside of the toe and spine fossils.

But studies of fossil bones alone, even with sophisticated imaging technology, provide “a very small window” for detecting cancers and tumors, cautions paleoanthropologist Janet Monge of the University of Pennsylvania Museum of Archaeology and Anthropology in Philadelphia. Microscopic analysis of soft-tissue cells, which are typically absent on fossils, confirms cancer diagnoses in people today, she says.

Without additional evidence of bone changes in and around the proposed cancer and tumor, Monge won’t draw any conclusions about what caused those growths.

Monge led a team that found a tumor on a 120,000- to 130,000-year-old Neandertal rib bone from Eastern Europe. Whether the tumor was cancerous or caused serious health problems can’t be determined, the scientists concluded in 2013 in PLOS ONE.

CHICAGO — Theoretical physicists are scratching their heads after scientists presented surprising new studies of a particle known as the bottom quark.

At the new, higher energies recently reached at the Large Hadron Collider particle accelerator, particles containing bottom quarks flew off at an angle more often than expected. Scientists reported the result August 4 at the International Conference on High Energy Physics.

Quarks make up larger particles like the proton and neutron. At the LHC, near Geneva, scientists smash together protons to produce new particles, including bottom quarks.
Those bottom quarks are bound together with other quarks into larger particles known as b hadrons. Scientists with LHCb, an experiment at the LHC, found an unexpected behavior in b hadrons that sped off at an angle from beams of colliding protons, rather than continuing on a nearly parallel trajectory. At high energies, the number of b hadrons flying off at an angle, relative to those at lower energies, was almost twice as large as expected.

The discrepancy could point to a problem with scientists’ predictions of how the particles should behave. Such predictions are based on the theory of how quarks interact, known as quantum chromodynamics, or QCD, which is important for grasping the inner workings of protons and neutrons. “Understanding QCD really sets the basis of our understanding of nature,” says LHCb member Marina Artuso of Syracuse University in New York.

Scientists who make predictions for how b hadrons should behave have had trouble explaining the discrepancy. “Whichever way you turn it, it’s really weird. Which to me, personally, makes it extremely exciting,” says theoretical physicist Michelangelo Mangano of CERN, the European particle physics lab that operates the LHC.

But, he cautioned, it’s unlikely to be an indication of phenomena that would upend the standard model of particle physics. Rather, it may be that calculations need further refinement, or that scientists need to tweak their understanding of the proton, by altering estimates of the momentum carried by the various particles found inside it.

The issue could also lie with LHCb’s measurement, but the scientists say they are very confident in their result. The team continues to study the data to better characterize the effect.

For the first time, scientists can see where molecular tags known as epigenetic marks are altered in the brain.

These chemical tags — which flag DNA or its protein associates, known as histones — don’t change the genes but can change gene activity. Abnormal epigenetic marks have been associated with brain disorders such as Alzheimer’s disease, schizophrenia, depression and addiction.

Researchers at Massachusetts General Hospital in Boston devised a tracer molecule that latches on to a protein that removes one type of epigenetic mark known as histone acetylation.

The scientists then used PET scans to detect where a radioactive version of the tracer appeared in the brains of eight healthy young adult men and women, the researchers report in the Aug. 10 Science Translational Medicine. Further studies could show that the marks change as people grow older or develop a disease. The team studied only healthy young volunteers so can’t yet say whether epigenetic marking changes with age or disease.